GSK launches £1.9 billion savings drive to fund drug pipeline

EarningsCorporate Action Impact 4
โดย Reuters·Read original
Summary · why it matters

GSK has launched a £1.9 billion cost-savings program to help fund late-stage studies and accelerate drug development. The three-year initiative aims to simplify the organization and reallocate capital and resources, CEO Luke Miels said in a statement. The British drugmaker also beat second-quarter profit expectations and announced a £400 million investment in the UK, including a new R&D centre. Shares rose 4.2% by 1120 GMT.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
GSK plc
GSK
▲ PositiveCapitalrelevance

GSK launched a £1.9B cost-savings program, beat Q2 profit expectations, and announced a £400M UK investment, driving shares up 4.2%.

© 2026 MarketDXNews